Abeona Therapeutics (ABEO) AI Stock Analysis

• Market Cap: $257.95M
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): 3.9
• Beta (1Y): 0.91
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 54,191,360
• 10 Day Avg. Volume: 1,294,247
• 30 Day Avg. Volume: 1,036,693
• PEG Ratio: -0.02
• Price to Book (P/B): 1.75
• Price to Sales (P/S): 47.95
• P/FCF Ratio: -3.31
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 35.13
• Enterprise Value/Gross Profit: 44.57
• Enterprise Value/Ebitda: 2.75
• 1Y Price Target: $22.67
• Price Target Upside: 376.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.42
• Revenue Forecast (FY): $95.11M

• Rating: 47 Neutral
• Price Target: $5.00 ▲(5.04% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by weak underlying financial performance (large operating losses and ongoing cash burn despite a stronger 2025 balance sheet) and soft technical momentum. Offsetting these is a more positive earnings-call outlook driven by reimbursement milestones (permanent J-code, broad payer coverage) and early commercialization ramp plans, though execution and adoption pace remain key risks.

Positive Factors

Strong cash position & improved capital structure

A large cash balance and stronger equity provide a multi‑quarter runway to fund commercialization, QTC onboarding and capacity expansion without immediate financing. This materially reduces near‑term liquidity risk and supports deliberate execution of commercial plans.

Durable reimbursement framework

A permanent J‑code plus broad commercial and Medicaid coverage creates a structural pathway for payment. That reduces reimbursement uncertainty per treated patient, improves revenue visibility as volumes grow, and supports sustainable commercial adoption over the medium term.

Built commercial infrastructure and scaling plan

An explicit plan to expand qualified treatment centers and manufacturing cadence provides durable operational capacity to scale treatments. Establishing site network and capacity is foundational to increasing throughput and improving per‑patient margins as adoption grows.

Negative Factors

Persistent negative operating cash flow

Sustained, sizable operating and free cash‑flow deficits mean the business relies on external financing unless commercial throughput scales quickly. Persistent cash burn constrains strategic flexibility, raises dilution/refinancing risk, and pressures management to accelerate revenue conversion.

Profitability highly sensitive to patient cadence

Management estimates break‑even depends on achieving ~3–3.5 patients/month per site. Given a 4–5 month consult‑to‑treatment cycle and early slow throughput, small setbacks in patient flow or site activation materially delay profitability and amplify operational execution risk.

Elevated commercial costs (SG&A) during ramp

A sharply higher SG&A base raises the revenue threshold required for sustainable profitability. Elevated fixed selling and administrative expenses magnify the financial impact of any delay in patient ramp, lengthening the timeline to operational break‑even and increasing execution risk.

Abeona Therapeutics Business Overview & Revenue Model

Company Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

How the Company Makes Money

null

Abeona Therapeutics Financial Statement Overview

Summary

Balance sheet improved materially in 2025 with higher equity and a sizable cash position, but the core business remains deeply unprofitable with volatile/low revenue and persistent, heavy operating and free-cash-flow burn. The 2025 net income gain appears largely non-operating and not reflective of sustainable earnings power.

Income Statement

Revenue is volatile and remains small for the scale of the cost base (2025 annual revenue of ~$5.8M after $0 in 2024). Operating losses are consistently large across the period (EBIT roughly -$47M to -$89M in most years), indicating the business is still heavily in investment/burn mode. A notable positive is 2025 net income of ~$71M, but this appears disconnected from operating performance given the deeply negative EBIT, suggesting one-time/non-operating items drove profitability rather than sustainable earnings power.

Balance Sheet

Leverage looks manageable: debt is moderate relative to equity, and the capital structure improved materially in 2025 with equity rising to ~$159M against ~$25M of debt (a much stronger cushion than prior years). Total assets also increased to ~$220M in 2025, supporting liquidity runway potential. The key weakness is that returns on equity have been strongly negative in prior years alongside persistent operating losses, meaning balance-sheet strength is currently funding operations rather than reflecting a self-sustaining business model.

Cash Flow

Cash generation remains a major concern: operating cash flow is consistently negative (about -$37M to -$76M annually), and free cash flow is also deeply negative (about -$37M to -$84M). The 2025 free cash flow burn worsened versus 2024, implying cash needs may be rising. Overall, the company appears reliant on external financing to fund operations until revenue and operating costs improve materially.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022
Income Statement
Total Revenue	5.82M	0.00	3.50M	1.41M	3.00M
Gross Profit	4.29M	-2.91M	1.90M	964.00K	3.00M
EBITDA	-89.45M	-56.62M	-50.57M	-34.38M	-76.82M
Net Income	71.18M	-63.73M	-54.19M	-39.70M	-84.94M
Balance Sheet
Total Assets	219.57M	108.93M	64.00M	64.21M	79.59M
Cash, Cash Equivalents and Short-Term Investments	191.40M	97.72M	52.23M	52.15M	45.02M
Total Debt	24.97M	23.05M	5.40M	7.63M	9.38M
Total Liabilities	60.35M	64.90M	49.18M	37.45M	37.22M
Stockholders Equity	159.22M	44.03M	14.83M	26.76M	42.37M
Cash Flow
Free Cash Flow	-84.30M	-58.46M	-37.34M	-43.61M	-69.82M
Operating Cash Flow	-76.33M	-56.02M	-37.01M	-43.48M	-65.67M
Investing Cash Flow	105.03M	-39.24M	208.00K	-23.96M	66.06M
Financing Cash Flow	26.04M	104.14M	37.06M	43.17M	24.86M

Abeona Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Negative. The current price of 4.76 is below the 20-day moving average (MA) of 5.06, below the 50-day MA of 5.11, and below the 200-day MA of 5.59, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.08 is Neutral, neither overbought nor oversold. The STOCH value of 24.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABEO.

Abeona Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$569.65M	-0.10	274.58%	―	―	-1072.48%
ABEO	47 Neutral	$257.95M	3.92	78.38%	―	―	―
GALT	46 Neutral	$203.11M	-8.32	―	―	―	18.82%
SLN	46 Neutral	$326.39M	-6.10	―	―	―	―
HUMA	45 Neutral	$223.88M	-3.93	853.54%	―	―	82.23%

Abeona Therapeutics Corporate Events

Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access

Abeona Therapeutics said on March 9, 2026, that commercial momentum is building for ZEVASKYN, its FDA-approved autologous gene therapy for wounds in patients with recessive dystrophic epidermolysis bullosa, following optimization of a key release assay in 2025. Commercial launch activities began in the fourth quarter of 2025, with the first patient treated in December ahead of a scheduled facility shutdown, and additional patients have entered the treatment and manufacturing queue since operations resumed in late January 2026.

The company reported strengthening market access, with coverage policies in place at all major U.S. commercial insurers representing about 80 percent of commercially insured lives, as well as across all Medicaid programs, and noted that ZEVASKYN has been assigned a permanent CMS J-code effective January 1, 2026 to facilitate billing and reimbursement. Abeona highlighted growing familiarity among Qualified Treatment Centers and rising interest from patients and physicians, which together suggest that early positive treatment experiences and streamlined reimbursement could underpin sustained demand and reinforce the company’s position in the emerging gene therapy market for rare dermatologic diseases.

The most recent analyst rating on (ABEO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.